The Feasibility of Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 11 Feb 2019
Price : $35 *
At a glance
- Drugs Lapatinib (Primary) ; Paclitaxel; Pegfilgrastim; Trastuzumab
- Indications Adenocarcinoma; Early breast cancer
- Focus Adverse reactions
- 31 Jan 2019 Status changed from discontinued to completed.
- 25 Jan 2019 Planned End Date changed from 1 Apr 2019 to 1 Apr 2020.
- 25 Jan 2019 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2020.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History